Eli Lilly has agreed to acquire privately held biopharma company SiteOne Therapeutics, adding a non-opioid-based pain treatment to the big pharma’s pipeline. The sale agreement will see Eli ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly LLY recently announced that it has entered into a definitive agreement to acquire the privately held clinical-stage company SiteOne Therapeutics in a deal valued at $1 billion.. Through ...

With the acquisition, Eli Lilly will gain access to SiteOne Therapeutics flagship product STC -004, a Phase 2 ready Nav1.8 inhibitor being developed as a non-opioid treatment for chronic pain.

Investing.com -- Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on ...

BMO reiterates Eli Lilly stock with $900 target on SiteOne deal ...

INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of ...

Eli Lilly LLY recently announced that it has entered into a definitive agreement to acquire the privately held clinical-stage company SiteOne Therapeutics in a deal valued at $1 billion.. Through this ...

On Wednesday, BMO Capital maintained its Outperform rating on Eli Lilly stock (NYSE: LLY), coupled with a steadfast price target of $900.00.With analyst targets ranging from $650 to $1,190 and a ...

On Wednesday, BMO Capital maintained its Outperform rating on Eli Lilly stock (NYSE: LLY), coupled with a steadfast price target of $900.00.With analyst targets ranging from $650 to $1,190 and a ...